Abstract
Using a real-time RT-PCR-based algorithm to detect SARS-CoV-2 variants of concern, we rapidly identified 77 variants (57-B.1.1.7, 7-B.1.351, and 13-B.1.1.28/P.1). This protocol enabled our laboratory to screen all SARS-CoV-2 positive samples for variants, and identified a cluster of B.1.1.28/P.1 cases, a variant not previously known to circulate in British Columbia.
Competing Interest Statement
This work was supported by COVID-19 rapid response grants from GenomeBC (COV-115 to ZLB, CFL; COV-033 to CJB), an Exceptional Opportunities Fund COVID-19 award from the Canada Foundation for Innovation (CJB, CFL), a British Columbia Ministry of Health Providence Health Care Research Institute COVID-19 Research Priorities Grant (CJB, CFL) and Public Health Agency of Canada COVID-19 Immunology Task Force COVID-19 Hot Spots Competition Grant (ZLB, MGR). GR reports participation as a Roche Diagnostics Sequencing Advisory Panel member. ZLB holds a Scholar Award from the Michael Smith Foundation for Health Research.
Funding Statement
This work was supported by COVID-19 rapid response grants from GenomeBC (COV-115 to ZLB, CFL; COV-033 to CJB), an Exceptional Opportunities Fund COVID-19 award from the Canada Foundation for Innovation (CJB, CFL), a British Columbia Ministry of Health Providence Health Care Research Institute COVID-19 Research Priorities Grant (CJB, CFL) and Public Health Agency of Canada COVID-19 Immunology Task Force COVID-19 Hot Spots Competition Grant (ZLB, MGR).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Providence Health Care/University of British Columbia and Simon Fraser University Research Ethics Boards (H20-01055).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Data available on request from the authors
